Literature DB >> 16132281

A decade of staged Norwood palliation in hypoplastic left heart syndrome in a midsized cardiosurgical center.

T Krasemann1, H Fenge, H-G Kehl, A Rukosujew, C Schmid, H-H Scheld, T D T Tjan, J Vogt.   

Abstract

Hypoplastic left heart syndrome (HLHS) is a challenge for the pediatric cardiologist and the surgeon. It is generally assumed that the postoperative outcome after surgery for congenital heart disease is influenced by the institutional size. We present the results of 43 patients with true HLHS (situs solitus and atrioventricular and ventriculoarterial concordance) referred for operation between 1992 and 2002 in our center. Two children had atrioseptostomy: one died soon after the operation, and the other one was transplanted successfully but died at the age of 6 months following acute rejection. The remaining 41 underwent Norwood I palliation, 21 stage II palliation, and 10 stage III palliation. Early mortality was 29% after stage I operation, 4.7% after stage II palliation, and 0% after stage III operation. Overall mortality was 39% after stage I, 9.5% after stage II, and 10% after stage III operation. Low birth weight was associated with a higher mortality (p < 0.05). Mortality declined with increasing experience, comparable to the results of very large cardiosurgical centers with many more patients. The quality of surgery and perioperative management in smaller pediatric cardiosurgical centers can reach the level of very large centers.

Entities:  

Mesh:

Year:  2005        PMID: 16132281     DOI: 10.1007/s00246-005-0908-5

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  18 in total

1.  [Anatomic and functional hypoplastic left heart syndrome and its surgical Norwood and Fontan treatment].

Authors:  W R Thies; T Breymann; E Cherlet; G Ertel; E Crespo-Martinez; W Matthies; R Körfer; H Meyer
Journal:  Z Kardiol       Date:  1997-07

2.  Current status of staged reconstruction for hypoplastic left heart syndrome.

Authors:  E L Bove
Journal:  Pediatr Cardiol       Date:  1998 Jul-Aug       Impact factor: 1.655

3.  Causes of death after the modified Norwood procedure: a study of 122 postmortem cases.

Authors:  U Bartram; J Grünenfelder; R Van Praagh
Journal:  Ann Thorac Surg       Date:  1997-12       Impact factor: 4.330

4.  Can regionalization decrease the number of deaths for children who undergo cardiac surgery? A theoretical analysis.

Authors:  Ruey-Kang R Chang; Thomas S Klitzner
Journal:  Pediatrics       Date:  2002-02       Impact factor: 7.124

5.  Pediatric cardiac surgery: the effect of hospital and surgeon volume on in-hospital mortality.

Authors:  E L Hannan; M Racz; R E Kavey; J M Quaegebeur; R Williams
Journal:  Pediatrics       Date:  1998-06       Impact factor: 7.124

6.  Physiologic repair of aortic atresia-hypoplastic left heart syndrome.

Authors:  W I Norwood; P Lang; D D Hansen
Journal:  N Engl J Med       Date:  1983-01-06       Impact factor: 91.245

7.  Survival after reconstructive surgery for hypoplastic left heart syndrome: A 15-year experience from a single institution.

Authors:  W T Mahle; T L Spray; G Wernovsky; J W Gaynor; B J Clark
Journal:  Circulation       Date:  2000-11-07       Impact factor: 29.690

8.  Evolving strategies and improving outcomes of the modified norwood procedure: a 10-year single-institution experience.

Authors:  T Azakie; S L Merklinger; B W McCrindle; G S Van Arsdell; K J Lee; L N Benson; J G Coles; W G Williams
Journal:  Ann Thorac Surg       Date:  2001-10       Impact factor: 4.330

9.  Outcomes after the Norwood operation in neonates with critical aortic stenosis or aortic valve atresia.

Authors:  David A Ashburn; Brian W McCrindle; Christo I Tchervenkov; Marshall L Jacobs; Gary K Lofland; Edward L Bove; Thomas L Spray; William G Williams; Eugene H Blackstone
Journal:  J Thorac Cardiovasc Surg       Date:  2003-05       Impact factor: 5.209

10.  Improved survival of patients undergoing palliation of hypoplastic left heart syndrome: lessons learned from 115 consecutive patients.

Authors:  James S Tweddell; George M Hoffman; Kathleen A Mussatto; Raymond T Fedderly; Stuart Berger; Robert D B Jaquiss; Nancy S Ghanayem; Stephanie J Frisbee; S Bert Litwin
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

View more
  4 in total

Review 1.  Nutrition algorithms for infants with hypoplastic left heart syndrome; birth through the first interstage period.

Authors:  Julie Slicker; David A Hehir; Megan Horsley; Jessica Monczka; Kenan W Stern; Brandis Roman; Elena C Ocampo; Liz Flanagan; Erin Keenan; Linda M Lambert; Denise Davis; Marcy Lamonica; Nancy Rollison; Haleh Heydarian; Jeffrey B Anderson
Journal:  Congenit Heart Dis       Date:  2012-08-14       Impact factor: 2.007

2.  Impact of prenatal diagnosis in survivors of initial palliation of single ventricle heart disease: analysis of the National Pediatric Cardiology Quality Improvement Collaborative database.

Authors:  David W Brown; Katie E Cohen; Patricia O'Brien; Kimberlee Gauvreau; Thomas S Klitzner; Robert H Beekman; John D Kugler; Gerard R Martin; Steven R Neish; Geoffrey L Rosenthal; Carole Lannon; Kathy J Jenkins
Journal:  Pediatr Cardiol       Date:  2014-08-19       Impact factor: 1.655

3.  Long-term outcome of palliation with internal pulmonary artery bands after primary heart transplantation for hypoplastic left heart syndrome.

Authors:  Shelley D Miyamoto; Biagio A Pietra; Kak-Chen Chan; David D Ivy; Christine Mashburn; David N Campbell; Max B Mitchell; Mark M Boucek
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

4.  Digoxin Use Is Associated With Reduced Interstage Mortality in Patients With No History of Arrhythmia After Stage I Palliation for Single Ventricle Heart Disease.

Authors:  David W Brown; Colleen Mangeot; Jeffrey B Anderson; Laura E Peterson; Eileen C King; Stacey L Lihn; Steven R Neish; Craig Fleishman; Christina Phelps; Samuel Hanke; Robert H Beekman; Carole M Lannon
Journal:  J Am Heart Assoc       Date:  2016-01-11       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.